Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droxidopa for Fatigue in Parkinsonism
NCT03446807Phase 2Withdrawn
- Sponsor
- Loma Linda University
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of droxidopa in Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), sponsored by Loma Linda University. Planned start Dec 2021; status: withdrawn.
02
Drugs
droxidopa
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03446807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446807.